Wei Tan
Assistant of Director, Head of Pharma
CCPIT Patent and Trademark Law Office
Personal Profile
Dr. Tan is the Assistant Director of the Chemical Department at the Patent and Trademark Office of the China Council for the Promotion of International Trade. With 16 years of experience in intellectual property, he provides comprehensive intellectual property services for well-known pharmaceutical companies and research institutes located in China or overseas. Dr. Tan is skilled in patent writing and provides strategic guidance for overseas intellectual property protection for domestic clients. He has also represented domestic and foreign clients in multiple invalidation reviews, administrative reviews, and patent litigation cases. Recent representative cases include:
(1) In 2023, on behalf of a well-known Japanese pharmaceutical company, we will respond to the invalidation request, first instance litigation and second instance litigation of a well-known domestic pharmaceutical company against three patents of the Japanese pharmaceutical company. All three cases of invalid litigation won the Supreme Court, and the invalid cases were rated as "Top Ten Cases of Invalid Patent Reexamination in 2019" by the Reexamination Committee of the China National Intellectual Property Administration;
(2) In 2023, represented a well-known American pharmaceutical company in responding to the invalidation request and first instance lawsuit filed by two major domestic pharmaceutical companies against the American pharmaceutical company's crystal patent, and won in the first instance court;
(3) In 2022, on behalf of well-known Japanese pharmaceutical companies, we will respond to a series of patent link cases of invalidity and drug determination put forward by well-known domestic pharmaceutical companies against the Japanese pharmaceutical companies' patents. The invalidity and drug determination series cases won the China National Intellectual Property Administration and the Supreme Court;
(4) In 2021, I represented a well-known German pharmaceutical company in responding to the invalidation request, first instance lawsuit, and second instance lawsuit filed by a pharmaceutical company in Beijing against the German pharmaceutical company's patent, and won in the Supreme Court. The second round of invalid cases against the patent also won in the China National Intellectual Property Administration recently.
(1) In 2023, on behalf of a well-known Japanese pharmaceutical company, we will respond to the invalidation request, first instance litigation and second instance litigation of a well-known domestic pharmaceutical company against three patents of the Japanese pharmaceutical company. All three cases of invalid litigation won the Supreme Court, and the invalid cases were rated as "Top Ten Cases of Invalid Patent Reexamination in 2019" by the Reexamination Committee of the China National Intellectual Property Administration;
(2) In 2023, represented a well-known American pharmaceutical company in responding to the invalidation request and first instance lawsuit filed by two major domestic pharmaceutical companies against the American pharmaceutical company's crystal patent, and won in the first instance court;
(3) In 2022, on behalf of well-known Japanese pharmaceutical companies, we will respond to a series of patent link cases of invalidity and drug determination put forward by well-known domestic pharmaceutical companies against the Japanese pharmaceutical companies' patents. The invalidity and drug determination series cases won the China National Intellectual Property Administration and the Supreme Court;
(4) In 2021, I represented a well-known German pharmaceutical company in responding to the invalidation request, first instance lawsuit, and second instance lawsuit filed by a pharmaceutical company in Beijing against the German pharmaceutical company's patent, and won in the Supreme Court. The second round of invalid cases against the patent also won in the China National Intellectual Property Administration recently.
